EPRX
vs
S
S&P TSX Composite Index (Canada)
EPRX
Over the past 12 months, EPRX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +78% compared to the S&P TSX Composite Index (Canada)'s +25% growth.
Stocks Performance
EPRX vs S&P TSX Composite Index (Canada)
Performance Gap
EPRX vs S&P TSX Composite Index (Canada)
Performance By Year
EPRX vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Eupraxia Pharmaceuticals Inc
Glance View
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.